Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s stock price shot up 3.1% during trading on Wednesday . The company traded as high as $8.74 and last traded at $8.58. 225,229 shares traded hands during trading, a decline of 20% from the average session volume of 282,151 shares. The stock had previously closed at $8.32.
Cybin Stock Up 2.8%
The stock has a fifty day simple moving average of $6.83 and a 200 day simple moving average of $8.36. The firm has a market capitalization of $189.43 million, a P/E ratio of -46.42 and a beta of 0.60.
Cybin Company Profile
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Recommended Stories
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
